Reata Pharma (RETA) Tops Q3 EPS by 89c; Reports Cash and Cash Equivalents of $713.2M

Reata Pharma (NASDAQ: RETA) reported Q3 EPS of ($1.27), $0.89 better than the analyst estimate of ($2.16). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $2.07 million.

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• SanDisk upgraded at JPMorgan after investor day; shares climb